| Old Articles: <Older 7491-7500 Newer> |
|---|
 |
The Motley Fool
May 31, 2011
Brian Orelli |
Too Many Drugs, Too Little Cash AVEO seals a deal with Johnson & Johnson.   |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
May 31, 2011
Brian Orelli |
Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good. |
The Motley Fool
May 30, 2011
Andrew Tonner |
Does Varian Medical Systems Deserve a Spot in Your Portfolio? Varian looks pretty attractive with above-average return on investment, margins, and fair growth. |
The Motley Fool
May 29, 2011
Andrew Tonner |
Does Watson Pharmaceuticals Deserve a Spot in Your Portfolio? Although Watson Pharmaceuticals doesn't look like a stock for your portfolio right now, the search doesn't end here. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
May 27, 2011
Andrew Tonner |
Does Zimmer Holdings Deserve a Spot in Your Portfolio? Compared to it's peers, Zimmer Holdings doesn't look like a stock for your portfolio right now. |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
May 27, 2011
Brian Orelli |
AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck. |
| <Older 7491-7500 Newer> Return to current articles. |
